A new study by researchers from Marshall University and the University of Missouri highlights how exosomes—tiny vesicles ...

Cells don’t just follow a rigid script when responding to stress – they’re far more adaptable than we thought. A new study ...

For decades microtubule-targeting agents (MTAs) have been a cornerstone of cancer treatment regimens and continue to be heavily employed as backbone chemotherapy in combination with new targeted ...

Rakovina will present two abstracts at the meeting, the first: Discovery of novel PARP1-selective inhibitors for treatment of brain tumors using artificial intelligence , explores the use of ...

CNS Pharmaceuticals (CNSP) announced the primary analysis of its clinical trial evaluating Berubicin, the first anthracycline demonstrated to ...

Mia Love, the first Black Republican woman elected to Congress, died three years after being diagnosed with glioblastoma, a ...

Learn how nanoparticles cross the blood-brain barrier (BBB) and explore their potential in treating neurological disorders ...

In an early-stage clinical trial, the therapy nearly doubled the expected survival time of young patients. Still, experts ...

Researchers of a new study have discovered that DSRD patients showed signs of neuroinflammation and blood-brain barrier ...

Japan's Ono Pharmaceutical is handing over $280 million upfront to acquire Ionis Pharmaceuticals’ phase 2-stage antisense oligonucleotide for a rare type of blood cancer. The RNA-targeted ...

Cytokines and chemokines (granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-8, tumor necrosis factor-alpha (TNF ... We have developed a “fetal blood-brain-barrier model”, and ...